Rena D. Callahan

867 total citations
12 papers, 629 citations indexed

About

Rena D. Callahan is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rena D. Callahan has authored 12 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rena D. Callahan's work include HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (2 papers). Rena D. Callahan is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Cancer Treatment and Pharmacology (4 papers) and Advanced Breast Cancer Therapies (2 papers). Rena D. Callahan collaborates with scholars based in United States and France. Rena D. Callahan's co-authors include Rosette Lidereau, Charles Theillet, J Gest, F. Spyratos, Chantal Escot, Sara A. Hurvitz, Gregory Campbell, Giorgio R. Merlo, Renato Mariani‐Costantini and A Gentile and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Rena D. Callahan

9 papers receiving 608 citations

Peers

Rena D. Callahan

ONCOL

RNMI

GENET

P.M.J.J. Berns Netherlands

Mitsuchika Hosoda Japan

Duen‐Hwa Yan United States

Louis‐François Plassa France

Sara Zaghlul United States

Farahnaz Forozan United States

U Vogt Germany

Roza Zandi Denmark

Hendrika M. Oosterkamp Netherlands

Amanda R. Wasylishen United States

P.M.J.J. Berns Netherlands

Rena D. Callahan

463 ×1.2

ONCOL

283 ×0.8

168 ×1.2

158 ×1.3

RNMI

137 ×1.2

GENET

Citations per year, relative to Rena D. Callahan Rena D. Callahan (= 1×) peers P.M.J.J. Berns

Countries citing papers authored by Rena D. Callahan

Since Specialization

Citations

This map shows the geographic impact of Rena D. Callahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rena D. Callahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rena D. Callahan more than expected).

Fields of papers citing papers by Rena D. Callahan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rena D. Callahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rena D. Callahan. The network helps show where Rena D. Callahan may publish in the future.

Co-authorship network of co-authors of Rena D. Callahan

This figure shows the co-authorship network connecting the top 25 collaborators of Rena D. Callahan. A scholar is included among the top collaborators of Rena D. Callahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rena D. Callahan. Rena D. Callahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Callahan, Rena D., et al.. (2026). Abstract PD5-05: Impact of circulating tumor DNA (ctDNA) surveillance on quality of life (QoL) for patients with early-stage breast cancer (EBC): prospective I-SURV study. Clinical Cancer Research. 32(4_Supplement). PD5–5.

Teysir, Jimmitti, Maxwell R. Lloyd, Rena D. Callahan, et al.. (2025). After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor–Positive Metastatic Breast Cancer. American Society of Clinical Oncology Educational Book. 45(3). e473372–e473372. 1 indexed citations

Lipsyc-Sharf, Marla, Arielle J. Medford, Mina S. Sedrak, et al.. (2024). Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study.. Journal of Clinical Oncology. 42(16_suppl). 549–549. 1 indexed citations

Hurvitz, Sara A., Julie Taguchi, David W. Chan, et al.. (2018). Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Therapeutic Advances in Medical Oncology. 10. 3861422379–3861422379. 25 indexed citations

Woo, Jennifer S., Neda A. Moatamed, Peggy Sullivan, et al.. (2015). Comparison of Phosphohistone H3 Immunohistochemical Staining, Ki-67, and H&E Mitotic Count in Invasive Breast Carcinoma. 1(1). 1. 2 indexed citations

Callahan, Rena D.. (2014). Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer. Journal of the Advanced Practitioner in Oncology. 5(2). 134–9. 2 indexed citations

Callahan, Rena D. & Sara A. Hurvitz. (2010). Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Current Opinion in Obstetrics & Gynecology. 23(1). 37–43. 71 indexed citations

Callahan, Rena D.. (1998). Somatic mutations that contribute to breast cancer.. PubMed. 63. 211–21. 15 indexed citations

Callahan, Rena D.. (1993). Mutations in breast cancer. European Journal of Cancer Prevention. 2(3). 131???132–131???132.

10.

Campbell, Gregory, et al.. (1988). Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma.. PubMed. 3(2). 139–46. 87 indexed citations

11.

Mariani‐Costantini, Renato, Charles Theillet, A Gentile, et al.. (1988). In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast.. PubMed. 48(1). 199–205. 79 indexed citations

12.

Escot, Chantal, Charles Theillet, Rosette Lidereau, et al.. (1986). Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.. Proceedings of the National Academy of Sciences. 83(13). 4834–4838. 346 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact